IDL Diagnostics (IDLDX) Q2 2024 earnings summary

Executive summary

• Revenue for Q2 2024 increased by 30% year-over-year to 15,273 KSEK, with strong growth in both bacteriology and oncology segments.

• Positive operating cash flow of 2,767 KSEK in Q2, a significant improvement from -2,342 KSEK in Q2 2023.

• Strategic review underway, focusing on growth and business development, supported by a strong cash position for potential acquisitions or in-licensing.

Financial highlights

• Q2 net sales: 15,273 KSEK (11,775 KSEK in Q2 2023); H1 net sales: 28,076 KSEK (22,828 KSEK in H1 2023).

• Q2 result after financial items: -13,054 KSEK (-15,490 KSEK in Q2 2023); H1: -23,594 KSEK (-29,158 KSEK in H1 2023), including goodwill amortization of 9,895 KSEK per quarter.

• Q2 EPS: -0.06 SEK (-0.07 SEK in Q2 2023); H1 EPS: -0.10 SEK (-0.13 SEK in H1 2023).

• Cash and cash equivalents at period end: 48,705 KSEK (57,548 KSEK at end of H1 2023).

• Equity at period end: 140,053 KSEK (193,537 KSEK at end of H1 2023).

Outlook and guidance

• Continued strong order intake and sales growth expected, with focus on expanding product portfolio and production capacity.

• Market for cancer diagnostics projected to grow from $10.9B in 2019 to $26.9B in 2027, driven by biomarker innovation.